The Global Immuno-oncology Therapeutics Market--Checkpoint Inhibitors

Friday, September 30, 2016 Cancer News J E 4

LONDON, Sept. 29, 2016 /PRNewswire/ -- The Next Generation of Cancer TherapiesImmuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibitors in the drug classes CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3, identifying companies and products in development, dollars spent at each phase (preclinical through launch), cost and reimbursement implications to payers, challenges to commercialization, and opportunities for pharmaceutical, biotech, or diagnostic companies as oncology treatment algorithms evolve. The study period is 2011 to 2020.

Market Snapshot

Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to tumor growth and progression.

Checkpoint Inhibitor Market: Market Snapshot, Global, 2015 Checkpoint pathways constitute the "checks and balances" segment of the immune system which facilitates the recognition of foreign substances or tumor cells by the T-cells.

Approximately 245 companies globally are developing therapies in the checkpoint inhibitor area, with over xx% in the United States. GLOBOCAN reported in 20xxan estimated 14.1 million new cases of cancer per year, with the projected incidence to rise to xx million by the year 20xx

The overall checkpoint inhibitor market is over $xx billion and is set to grow at a CAGR of xx% (20xx–20xx.

- Although the US dominates the market, because of the exorbitant drug development investments, new opportunities do exist in Europe and Japan where cancer incidence is increasing.

- Analysts have estimated the potential of the total immuno-oncology market peak sales to be worth $xx to $xx billion by 20xx with more product approvals and indication expansions for existing products.

Download the full report: ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +44 208 816 85 48 Website:

To view the original version on PR Newswire, visit:

SOURCE ReportBuyer



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
i3system Thermal Expert IR camera and microbolomet...
A Punitive Double Bind: Families Suffer When State...